The US Department of Health and Human Services’ Health Resources and Services Administration (HRSA) on Monday sent letters to six major drug manufacturers, warning them that they could face steep fines if they don’t discount drug prices for pharmacies that contract with 340B providers. The letters were sent to AstraZeneca, Lilly USA, Novartis, Novo Nordisk, Sanofi and United Therapeutics. The letters follow an advisory opinion issued by HRSA in December.
The HHS actions follow letters from WSHA and other organizations and a lawsuit from 340B entities exhorting HHS to take action against drug manufacturers that were restricting or denying sales to 340B entities.(Andrew Busz, AndrewB@wsha.org)